 |
|
| ICRP PUBLICATION 94: RELEASE OF PATIENTS AFTER THERAPY WITH UNSEALED RADIONUCLIDES, 94
| |
| | |
|
|
 To order this title, and for more information, click here
By
. International Commission on Radiological Protection
Included in series
International Commission on Radiological Protection, 94
Description
After some therapeutic nuclear medicine procedures with unsealed radionuclides, precautions may be needed to limit doses to others, but
this is rarely the case after diagnostic procedures. Iodine-131 results in the most dose to medical staff, public, caregivers, and family
members. Other radionuclides used in therapy are usually simple beta emitters (e.g. 32P, 89Sr, 90Y) that pose much less hazard. Dose
limits apply to the exposure of the public and medical staff from patients. Prior ICRP recommendations are that no dose limit but a source-related
dose constraint for optimisation of a few mSv per episode applies to the family, visitors, and caregivers at home. Here, it is recommended
that young children and infants, as well as visitors not engaged in direct care or comforting, be treated as members of the public (i.e.,
be subject to the public dose limit).
Contents
TYPES AND FREQUENCY OF NUCLEAR MEDICINE
PROCEDURES
RADIATION PROTECTION AFTER USE OF THERAPEUTIC
RADIOPHARMACEUTICALS
CURRENT
INTERNATIONAL RECOMMENDATIONS ON DOSE
LIMITS AND DOSE CONSTRAINTS
CRITICAL PATHWAYS OF EXPOSURE FROM IODINE-131>BR>
MAGNITUDE AND
NATURE OF RISK FROM IODINE-131
EXPOSURE FOR RELATIVES, CAREGIVERS, AND THE PUBLIC
ENVIRONMENTAL PATHWAYS OF RADIOIODINE
DISPOSAL
OF RADIOACTIVE WASTE FROM THERAPY WITH
UNSEALED RADIONUCLIDES
DECISION TO HOSPITALISE OR RELEASE PATIENTS
INTERNATIONAL AND NATIONAL
GUIDANCE ON RELEASE
CRITERIA
ANTIBODY THERAPY
Bibliographic & ordering Information
Paperback, publication date: APR-2005
ISBN-13: 978-0-08-044560-1
ISBN-10: 0-08-044560-8
Imprint: ELSEVIER
063/663
Last update: 10 Jul 2008
|
|
| |
| | |
|
|
| |
